CLVS earnings call for the period ending September 30, 2019.
News & Analysis: Clovis Oncology
Wall Street is questioning the value and purpose of a recent deal.
The company reported a net loss of $120 million for the second quarter, which was much worse than analysts expected.
The company decided to discontinue an important clinical trial.
Better-than-expected Rubraca sales were just what investors wanted to see.
The down-on-its-luck pharma company turned in a solid year of growth. Will it be enough to remain competitive -- or find a suitor?
Three separate unfavorable events sent investors packing. Were things really that bad?
The biopharma reported struggles during the third quarter of 2018.
The biopharma stock fell on excellent news -- for the competition.
Initial results from an ongoing study failed to excite the crowd at an important medical conference.
Shares retreated after the company reported mixed quarterly results.